Cohen Douglas Jay 4
4 · VivoSim Labs, INC. · Filed Jan 29, 2026
Research Summary
AI-generated summary of this filing
VivoSim (VIVS) Director Cohen Receives 15,000-Share Award
What Happened Douglas Jay Cohen, a director of VivoSim Labs, Inc. (VIVS), was granted 15,000 restricted stock units (RSUs) on January 27, 2026. The award was reported as an acquisition at $0.00 per share (total reported value $0). This filing documents a compensation award (grant), not an open‑market purchase or sale.
Key Details
- Transaction date: 2026-01-27; Form 4 filed: 2026-01-29.
- Transaction type/code: Award/Grant (code A).
- Amount: 15,000 RSUs; reported acquisition price $0.00; reported total $0.
- Vesting: RSUs vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders; vesting may accelerate on a change of control (Footnote F1).
- Reverse split: All share numbers reflect a 1-for-12 reverse split effective March 20, 2025 (Footnote F2).
- Shares owned after transaction: Not specified in this filing.
- Filing timeliness: Filed two days after the transaction date; no late-filing indicator. Exhibit 24 (Power of Attorney) is attached.
Context RSUs are compensation that convert to actual shares only when they vest; until then they typically cannot be sold and may be forfeited if vesting conditions aren't met. Grants like this are common for director compensation and do not by themselves indicate insider buying or selling sentiment.
Insider Transaction Report
Form 4
Cohen Douglas Jay
Director
Transactions
- Award
Common Stock
[F1][F2]2026-01-27+15,000→ 20,732 total
Holdings
- 83(indirect: By Son)
Common Stock
[F2] - 83(indirect: By Daughter)
Common Stock
[F2]
Footnotes (2)
- [F1]The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.
- [F2]Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.
Signature
/s/ Norman Staskey, attorney-in-fact|2026-01-29